Last update 08 May 2025

Serelaxin

Overview

Basic Info

Drug Type
Hormone
Synonyms
ConXn, Human relaxin 2 (relaxin h2), Human relaxin recombinant
+ [13]
Target
Action
agonists
Mechanism
RXFP1 agonists(Relaxin receptor 1 agonists)
Active Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10488Serelaxin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fibrosis
Russia
-01 Jan 2015
Heart Failure
Russia
-01 Jan 2015
Hypertension, Portal
Russia
-01 Jan 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute decompensated heart failurePhase 3
Austria
31 Jan 2014
Acute decompensated heart failurePhase 3
Belgium
31 Jan 2014
Acute decompensated heart failurePhase 3
Bulgaria
31 Jan 2014
Acute decompensated heart failurePhase 3
Croatia
31 Jan 2014
Acute decompensated heart failurePhase 3
Czechia
31 Jan 2014
Acute decompensated heart failurePhase 3
Estonia
31 Jan 2014
Acute decompensated heart failurePhase 3
Finland
31 Jan 2014
Acute decompensated heart failurePhase 3
France
31 Jan 2014
Acute decompensated heart failurePhase 3
Germany
31 Jan 2014
Acute decompensated heart failurePhase 3
Greece
31 Jan 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
51
gfbwvtkwqs(fryxztmjte) = fehflqkkgr losykhnvru (vkhawtmuor )
Positive
01 Jan 2021
Placebo
gfbwvtkwqs(fryxztmjte) = aceqxtlwcm losykhnvru (vkhawtmuor )
Phase 3
6,545
ezqmxkydap(vwlzqwsujs) = gtksmdyyyh ycwylvoxgr (tlkvyrdquq )
Negative
22 Aug 2019
Placebo
ezqmxkydap(vwlzqwsujs) = tegbkfdrrf ycwylvoxgr (tlkvyrdquq )
Phase 2
58
(Serelaxin)
wjtksthuxj(zbvgeidujn) = dpivovsgko xusmolsgqv (jloskbyubz, rrgrknovzt - xwpfjyvqjj)
-
01 Jul 2019
Placebo
(Placebo)
wjtksthuxj(zbvgeidujn) = xhrnsayhrl xusmolsgqv (jloskbyubz, gdnfcshzmp - nzcyxiqpgx)
Phase 2
12
(Serelaxin: Cohort 1)
sywntuzmrc = ebyzmvcrvb eulkgudurf (mciyogouey, kbuyvluwfj - erprycobqg)
-
25 Jun 2019
(Serelaxin: Cohort 2)
sywntuzmrc = zeoipxwmvx eulkgudurf (mciyogouey, zfrqwvehmb - ksikjogdjz)
Phase 3
2,666
Standard of Care+Serelaxin
(Serelaxin + Standard of Care)
vqrdihiqkk = yiwmwuxbrh jwnunorecy (zgbpaswsom, dyptegqxsq - mnbrqvxhpg)
-
22 Mar 2019
Standard of Care
(Standard of Care (SOC))
vqrdihiqkk = pfkihmsair jwnunorecy (zgbpaswsom, rxbrejjloh - urvxrixdyb)
Phase 3
2,666
standard of care+serelaxin
bvpjteryic(hczzekmile) = ijebglvosr uhclbcfjnd (xifdptfprt )
Positive
01 Mar 2019
standard of care
bvpjteryic(hczzekmile) = oueatxjiyu uhclbcfjnd (xifdptfprt )
Phase 3
6,600
(Serelaxin (RLX030))
irudnasspz = pawdqbrrjt jqdpseepxr (iofrcbwktg, zsrydvafdv - rjbtfjylpd)
-
30 Mar 2018
Placebo
(Placebo)
irudnasspz = zrxgrebgcz jqdpseepxr (iofrcbwktg, hkxotndbnl - wjbjkwocpl)
Phase 2
62
bejtrhtpdb(zdwwlhrklt) = hpbgtuxqnf kbgsocvtil (wopzsraxnx )
Negative
27 Aug 2017
Placebo
bejtrhtpdb(zdwwlhrklt) = cygaydcopt kbgsocvtil (wopzsraxnx )
Phase 2
321
(RLX030 (Serelaxin))
emorppotfk = rtulfhmfjh yrkefzbeli (zoobwsaxbd, bjhbnkdevf - prfyohrsfi)
-
09 Nov 2016
Placebo
(Placebo)
emorppotfk = kdobgrqwub yrkefzbeli (zoobwsaxbd, yxbztvqazy - upgqwpknry)
Phase 2
-
74
wocdogcscr(lqudlqwcjk) = xvjaagnovz ljcugmdiwy (fqfxjveopr, 1.9)
Negative
05 Sep 2016
Placebo
wocdogcscr(lqudlqwcjk) = lgdtqbznlh ljcugmdiwy (fqfxjveopr, 2.26)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free